Medscape recently launched a new education opportunity for healthcare providers.
The activity reviews current treatment options for hemophilia A, challenges to optimal treatment, and future research directions.
NHF is aware that recently Shire sought an injunction against Roche/Genentech.
BioMarin provided a series of updates on their investigational hemophilia A gene therapy candidate valoctocogene roxaparvovec.
The FDA has lifted a hold on clinical studies involving the investigational therapy fitusiran.
This agreement allows Shire to conduct research on the use of Rani Pill™ technology for the oral delivery of factor VIII therapy for patients with hemophilia A.
Spark provided clinical trial updates on the company’s investigational gene therapies for hemophilia A and B, SPK-8011 and SPK-9001.
Genentech recently reported results from the phase III HAVEN 3 study, which showed that the prophylactic use of HEMLIBRA® led to significantly reduced bleeds in adult and adolescent patients with h
NHF is pleased to announce Christopher J. Ng, MD, Assistant Professor of Pediatrics, University of Colorado Denver, as the recipient of the 2017 NHF/Novo Nordisk Career Development Award (CDA).
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car